149 related articles for article (PubMed ID: 18091608)
21. Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships.
Soy D; Aweeka FT; Church JA; Cunningham CK; Palumbo P; Kosel BW; Sheiner LB;
Clin Pharmacol Ther; 2003 Dec; 74(6):569-80. PubMed ID: 14663459
[TBL] [Abstract][Full Text] [Related]
22. Enfuvirtide approved for defusing HIV.
Burton A
Lancet Infect Dis; 2003 May; 3(5):260. PubMed ID: 12726955
[No Abstract] [Full Text] [Related]
23. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: Inverse Gaussian density absorption and 2-compartment disposition.
Zhang X; Nieforth K; Lang JM; Rouzier-Panis R; Reynes J; Dorr A; Kolis S; Stiles MR; Kinchelow T; Patel IH
Clin Pharmacol Ther; 2002 Jul; 72(1):10-9. PubMed ID: 12152000
[TBL] [Abstract][Full Text] [Related]
25. Enfuvirtide.
Lalezari JP; Luber AD
Drugs Today (Barc); 2004 Mar; 40(3):259-69. PubMed ID: 15148534
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.
Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M;
N Engl J Med; 2003 May; 348(22):2186-95. PubMed ID: 12773645
[TBL] [Abstract][Full Text] [Related]
27. Reassessment of enfuvirtide's role in the management of HIV-1 infection.
Marr P; Walmsley S
Expert Opin Pharmacother; 2008 Sep; 9(13):2349-62. PubMed ID: 18710359
[TBL] [Abstract][Full Text] [Related]
28. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
Pham PA
Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
[No Abstract] [Full Text] [Related]
29. Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties.
Cheng S; Wang Y; Zhang Z; Lv X; Gao GF; Shao Y; Ma L; Li X
Eur J Med Chem; 2016 Oct; 121():232-237. PubMed ID: 27240277
[TBL] [Abstract][Full Text] [Related]
30. Enfuvirtide and cutaneous injection-site reactions.
Mirza RA; Turiansky GW
J Drugs Dermatol; 2012 Oct; 11(10):e35-8. PubMed ID: 23134996
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.
Wiznia A; Church J; Emmanuel P; Eppes S; Rowell L; Evans C; Bertasso A;
Pediatr Infect Dis J; 2007 Sep; 26(9):799-805. PubMed ID: 17721374
[TBL] [Abstract][Full Text] [Related]
32. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Nelson M; Arastéh K; Clotet B; Cooper DA; Henry K; Katlama C; Lalezari JP; Lazzarin A; Montaner JS; O'Hearn M; Piliero PJ; Reynes J; Trottier B; Walmsley SL; Cohen C; Eron JJ; Kuritzkes DR; Lange J; Stellbrink HJ; Delfraissy JF; Buss NE; Donatacci L; Wat C; Smiley L; Wilkinson M; Valentine A; Guimaraes D; Demasi R; Chung J; Salgo MP
J Acquir Immune Defic Syndr; 2005 Dec; 40(4):404-12. PubMed ID: 16280694
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Meng Q; Dong T; Chen X; Tong B; Qian X; Che J; Cheng Y
J Pharm Sci; 2014 Dec; 103(12):4038-4047. PubMed ID: 25291974
[TBL] [Abstract][Full Text] [Related]
34. Peptide inhibitors of virus-cell fusion: enfuvirtide as a case study in clinical discovery and development.
Cooper DA; Lange JM
Lancet Infect Dis; 2004 Jul; 4(7):426-36. PubMed ID: 15219553
[TBL] [Abstract][Full Text] [Related]
35. Enfuvirtide (T-20): potentials and challenges.
Foy K; Juethner SN
J Assoc Nurses AIDS Care; 2004; 15(6):65-71. PubMed ID: 15538017
[TBL] [Abstract][Full Text] [Related]
36. Enfuvirtide.
Dando TM; Perry CM
Drugs; 2003; 63(24):2755-66; discussion 2767-8. PubMed ID: 14664654
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro.
Dai SJ; Dou GF; Qiang XH; Song HF; Tang ZM; Liu DS; Liu XW; Yang LM; Zheng YT; Liang Q
Acta Pharmacol Sin; 2005 Oct; 26(10):1274-80. PubMed ID: 16174446
[TBL] [Abstract][Full Text] [Related]
38. Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?
Maggi P; Filotico R; Bonora S; Volpe A; Bellacosa C; Cinori E; de Requena DG; D'Avolio A; Di Perri G
Clin Drug Investig; 2008; 28(5):305-11. PubMed ID: 18407716
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of enfuvirtide in a patient with impaired renal function.
Leen C; Wat C; Nieforth K
Clin Infect Dis; 2004 Dec; 39(11):e119-21. PubMed ID: 15578350
[TBL] [Abstract][Full Text] [Related]
40. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
